These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 38975334)
1. Heterologous booster vaccination enhances antibody responses to SARS-CoV-2 by improving Tfh function and increasing B-cell clonotype SHM frequency. Song Y; Wang J; Yang Z; He Q; Bao C; Xie Y; Sun Y; Li S; Quan Y; Yang H; Li C Front Immunol; 2024; 15():1406138. PubMed ID: 38975334 [TBL] [Abstract][Full Text] [Related]
2. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956 [TBL] [Abstract][Full Text] [Related]
3. High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells. Chen JS; Chow RD; Song E; Mao T; Israelow B; Kamath K; Bozekowski J; Haynes WA; Filler RB; Menasche BL; Wei J; Alfajaro MM; Song W; Peng L; Carter L; Weinstein JS; Gowthaman U; Chen S; Craft J; Shon JC; Iwasaki A; Wilen CB; Eisenbarth SC Sci Immunol; 2022 Feb; 7(68):eabl5652. PubMed ID: 34914544 [TBL] [Abstract][Full Text] [Related]
4. Follicular T cells optimize the germinal center response to SARS-CoV-2 protein vaccination in mice. Cavazzoni CB; Hanson BL; Podestà MA; Bechu ED; Clement RL; Zhang H; Daccache J; Reyes-Robles T; Hett EC; Vora KA; Fadeyi OO; Oslund RC; Hazuda DJ; Sage PT Cell Rep; 2022 Feb; 38(8):110399. PubMed ID: 35139367 [TBL] [Abstract][Full Text] [Related]
5. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination. Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402 [TBL] [Abstract][Full Text] [Related]
6. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Spencer AJ; McKay PF; Belij-Rammerstorfer S; Ulaszewska M; Bissett CD; Hu K; Samnuan K; Blakney AK; Wright D; Sharpe HR; Gilbride C; Truby A; Allen ER; Gilbert SC; Shattock RJ; Lambe T Nat Commun; 2021 May; 12(1):2893. PubMed ID: 34001897 [TBL] [Abstract][Full Text] [Related]
7. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Wang X; Zhao X; Song J; Wu J; Zhu Y; Li M; Cui Y; Chen Y; Yang L; Liu J; Zhu H; Jiang S; Wang P Emerg Microbes Infect; 2022 Dec; 11(1):477-481. PubMed ID: 35034583 [TBL] [Abstract][Full Text] [Related]
8. Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting. Younes S; Nicolai E; Younes N; Pieri M; Bernardini S; Nizamuddin PB; Al-Sadeq DW; Daas HI; Ismail A; Yassine HM; Abu-Raddad LJ; Nasrallah GK Vaccine; 2024 Oct; 42(23):126042. PubMed ID: 38845303 [TBL] [Abstract][Full Text] [Related]
9. Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters. Agbayani G; Akache B; Renner TM; Tran A; Stuible M; Dudani R; Harrison BA; Duque D; Bavananthasivam J; Deschatelets L; Hemraz UD; Régnier S; Durocher Y; McCluskie MJ Eur J Immunol; 2024 Jun; 54(6):e2350620. PubMed ID: 38561974 [TBL] [Abstract][Full Text] [Related]
10. Follicular Helper T Cells in the Immunopathogenesis of SARS-CoV-2 Infection. Cui D; Tang Y; Jiang Q; Jiang D; Zhang Y; Lv Y; Xu D; Wu J; Xie J; Wen C; Lu L Front Immunol; 2021; 12():731100. PubMed ID: 34603308 [TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. Alsoussi WB; Malladi SK; Zhou JQ; Liu Z; Ying B; Kim W; Schmitz AJ; Lei T; Horvath SC; Sturtz AJ; McIntire KM; Evavold B; Han F; Scheaffer SM; Fox IF; Mirza SF; Parra-Rodriguez L; Nachbagauer R; Nestorova B; Chalkias S; Farnsworth CW; Klebert MK; Pusic I; Strnad BS; Middleton WD; Teefey SA; Whelan SPJ; Diamond MS; Paris R; O'Halloran JA; Presti RM; Turner JS; Ellebedy AH Nature; 2023 May; 617(7961):592-598. PubMed ID: 37011668 [TBL] [Abstract][Full Text] [Related]
12. Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells. Wietschel KA; Fechtner K; Antileo E; Abdurrahman G; Drechsler CA; Makuvise MK; Rose R; Voß M; Krumbholz A; Michalik S; Weiss S; Ulm L; Franikowski P; Fickenscher H; Bröker BM; Raafat D; Holtfreter S Front Immunol; 2024; 15():1382911. PubMed ID: 38807606 [TBL] [Abstract][Full Text] [Related]
14. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program. van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH; Front Immunol; 2024; 15():1390022. PubMed ID: 38698851 [TBL] [Abstract][Full Text] [Related]
16. Early T Follicular Helper Cell Responses and Germinal Center Reactions Are Associated with Viremia Control in Immunized Rhesus Macaques. Helmold Hait S; Vargas-Inchaustegui DA; Musich T; Mohanram V; Tuero I; Venzon DJ; Bear J; Rosati M; Vaccari M; Franchini G; Felber BK; Pavlakis GN; Robert-Guroff M J Virol; 2019 Feb; 93(4):. PubMed ID: 30463978 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up. Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice. Yang H; Xie Y; Li S; Bao C; Wang J; Li C; Nie J; Quan Y Hum Vaccin Immunother; 2024 Dec; 20(1):2364519. PubMed ID: 38880868 [TBL] [Abstract][Full Text] [Related]
19. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Jung SY; Kang KW; Lee EY; Seo DW; Kim HL; Kim H; Kwon T; Park HL; Kim H; Lee SM; Nam JH Vaccine; 2018 Jun; 36(24):3468-3476. PubMed ID: 29739720 [TBL] [Abstract][Full Text] [Related]
20. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2. Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M Front Immunol; 2022; 13():811020. PubMed ID: 35126395 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]